NETHERLANDS TRANSLATIONAL RESEARCHCENTER BV

Their core work

NTRC is a Dutch biomedical SME based in Oss — a city with deep roots in pharma — that specializes in translating laboratory oncology science into clinically applicable tools. Their demonstrated work centers on validating prognostic biomarkers found in liquid biopsies to predict how cancer patients will respond to chemotherapy, a field with direct diagnostic and treatment-planning value. They also contribute expertise in cell biology, specifically the mechanics of epithelial cell motility, by hosting or supporting researcher training through European networks. As a translational research center, their core function is to close the gap between what scientists discover in the lab and what clinicians and diagnostics companies can actually use.

What they specialise in

How they've shifted over time

Both H2020 projects began in 2015, so there is no meaningful temporal shift in focus across the H2020 period — the dataset does not support a before-and-after narrative. What the two projects together suggest is a consistent positioning at the intersection of fundamental cell biology and applied cancer diagnostics from the outset. Without later-stage projects, it is impossible to confirm whether NTRC deepened into liquid biopsy diagnostics, pivoted toward a different disease area, or scaled commercially after the SME Instrument feasibility phase.

With only 2015-era projects in the record, the trajectory is unclear — but the SME Instrument coordinator role in liquid biopsy diagnostics suggests a commercially-oriented biotech, and anyone considering a collaboration should verify whether NTRC has continued developing products or services in precision oncology since then.

How they like to work

NTRC demonstrates a dual mode: they led a small SME Instrument feasibility project (SENSITIVITYMARKERS) as coordinator, indicating they can drive focused clinical validation work independently, and they participated as a third party in a large MSCA training network (InCeM), suggesting they also contribute specialist hosting or mentoring capacity to wider consortia. The 28 unique consortium partners and 8 countries in their network are almost certainly inherited from InCeM, which as a Research Training Network typically involves a broad academic-industrial consortium. This means NTRC has consortium experience beyond its size, but its own coordination history is limited to a single small-scale project.

NTRC has touched 28 unique consortium partners across 8 European countries, a network footprint that exceeds what would be expected from a 2-project SME. This breadth traces primarily to the InCeM training network, which brought academic institutions and industry partners together across multiple countries.

What sets them apart

NTRC occupies a specific and commercially relevant niche: clinical biomarker validation for cancer treatment response, delivered by a small specialized company rather than a large academic hospital or CRO. Being based in Oss — historically a pharma hub home to Organon and Johnson & Johnson facilities — gives them proximity to industrial pharma networks that pure academic groups lack. For consortium builders in precision oncology or diagnostics, they offer the combination of SME agility, translational focus, and the credibility of having won a competitive EU SME Instrument grant as coordinator.

Highlights from their portfolio

• SENSITIVITYMARKERS
  NTRC coordinated this SME Instrument Phase 1 project — a competitive grant awarded to commercially-promising SMEs — focused on clinical validation of liquid biopsy biomarkers for predicting chemotherapy response, which is both scientifically and commercially high-value in oncology.
• InCeM
  Participation as a third party in this MSCA Innovative Training Network on epithelial cell motility shows NTRC's connection to fundamental cell biology research and European academic training networks, broadening their profile beyond pure diagnostics.